Winzelers believes that latah is less demeaning for women than it is for men, and that women actually have more freedom in society because they are not held to as strict of standards as men are. He argues that as men age, they become more concerned with personal dignity and poise while women become less so. Because of this, women feel more freedom to engage in latah behavior, while men do not. See also
Hyperekplexia
Tourette syndrome
Tic

References
Further reading
Kenny, MG (1978). "LATAH: The symbolism of a putative mental disorder". Culture, Medicine and Psychiatry. 2 (3): 209–231. doi:10.1007/BF00051005. PMID 710172. S2CID 29736522. Simons, RC (November 2001). "Introduction to Culture-Bound Syndromes". Psychiatric Times. XVIII (11). "Nova et Vetera". British Medical Journal. 1 (2669): 438–46. 24 February 1912. doi:10.1136/bmj.1.2669.438-a. PMC 2345217. PMID 20766030. "Special Correspondence". British Medical Journal. 1 (1423): 763–765. 7 April 1888. doi:10.1136/bmj.1.1423.763. PMC 2197720.
Agalsidase beta, sold under the brand name Fabrazyme by the company Sanofi Genzyme, is another recombinant form of alpha-galactosidase. Like replagal, it received approval in the EU in 2001. In 2003, it was the first treatment for Fabry disease to be approved by the FDA.Clinically, the two treatments are generally similar in effectiveness and safety, however they have never been compared directly in a randomized trial. Both are given by intravenous infusion every two weeks. They are available in Europe and in many other parts of the world, but treatment costs remain very high.Pharmacological chaperone therapy is another strategy to maintain enzyme activity. It does so by assisting correct folding of alpha-galactosidase despite the mutations that cause Fabry disease. As of March 2022, one medical drug based on pharmacological chaperone therapy is available for Fabry disease:
Migalastat, sold under the brand name Galafold by the company Amicus Therapeutics, is a pharmacological chaperone that can stabilize many mutant forms of alpha-galactosidase. It is taken by mouth. In a randomized trial comparing Migalastat with enzyme replacement therapy, the efficacy and safety of both treatments were similar. The US Food and Drug Administration (FDA) granted Galafold orphan drug status in 2004, and the European Commission followed in 2006. The European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) granted the drug a marketing approval under the name Galafold in May 2016. FDA approval followed in 2018.